Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | TACR2 | P21452 | 2/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.31 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1768779 | 1.00 | MMP1 (0.36) | MMP1F10TACR2ACEPRMT5 | |
| SCHEMBL1768410 | 0.89 | MMP1 (0.37) | MMP1F10TACR2PRMT5WDR77 | |
| SCHEMBL1768413 | 0.89 | MMP1 (0.37) | MMP1F10TACR2PRMT5WDR77 | |
| SCHEMBL13585826 | 0.84 | F10 (0.40) | MMP1F10TACR2PRMT5WDR77 | |
| SCHEMBL13585827 | 0.84 | F10 (0.40) | MMP1F10TACR2PRMT5WDR77 | |
| SCHEMBL13584922 | 0.81 | F10 (0.38) | MMP1F10TACR2PRCPTBXAS1 | |
| SCHEMBL13584925 | 0.81 | F10 (0.38) | MMP1F10TACR2PRCPTBXAS1 | |
| SCHEMBL13585823 | 0.80 | PRMT5 (0.41) | MMP1F10TACR2ACEPRMT5 | |
| SCHEMBL13585819 | 0.80 | PRMT5 (0.41) | MMP1F10TACR2ACEPRMT5 | |
| SCHEMBL13585091 | 0.77 | ACE (0.40) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754038-B2 | Template-fixed peptidomimetics with CCR10 antagonistic activity | POLYPHOR AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2012-11-08 | — | — | US | disclosed |
| EP-2501715-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY | Polyphor Ag (CH) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011060937-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY | POLYPHOR AG (CH) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | CCR10, CCR1, CCRL2 | MMP1 2630/4885F10 257/4885TACR2 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.